Compare Eli Lilly And Co (LLY) vs PulteGroup, Inc. (PHM) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

PulteGroup (PHM) trades at $123.12, down 2.35% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows solid fundamentals with a P/E of 12.19, net income margin of 12.14%, and positive cash flow trends, though recent earnings missed expectations in two of the last three quarters. Recent news highlights mixed investor sentiment amid mortgage rate concerns and new community developments, with a dividend payment scheduled for July 2, 2026.

Outlook is cautiously optimistic with a consensus price target of $146.50, implying 19% upside, supported by strong institutional holdings and a GF Score of 93. Key risks include high mortgage rates pressuring margins and volatile housing demand. The stock's current level near the analyst low target of $123.00 suggests potential support, but earnings performance in the upcoming Q2 report will be critical for momentum.